Cybin Inc.

CLXPF

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2025-01-14 pm EST			5-day change	1st Jan Change
8.830 ^USD	-0.79%		-11.96%	+0.11%

Dec. 11	Cybin Inc. - Special Call
Nov. 18	Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year	MT

Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year

November 18, 2024 at 08:12 am EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Cybin Inc.

Cybin Inc. - Special Call	Dec. 11
Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year	Nov. 18	MT
Cybin Inc. - Special Call	Nov. 18
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder	Nov. 18	CI
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Nov. 13	CI
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results	Nov. 13	CI
Cybin Inc. - Special Call	24-10-08
Cybin Inc. Announces Executive Appointments	24-10-01	CI
Cybin Inc.(NYSEAM:CYBN) added to S&P Global BMI Index	24-09-22	CI
Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones	24-09-20	CI
Cybin Inc. - Shareholder/Analyst Call	24-08-27
Cybin to Begin Phase 3 Trial of Treatment for Major Depressive Disorder This Summer	24-08-13	MT
Cybin Inc. Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder	24-08-13	CI
Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee	24-08-13	CI
Cybin Inc. Reports Earnings Results for the First Quarter Ended June 30, 2024	24-08-08	CI
Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	24-06-26	CI
Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development	24-06-11	CI
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	24-05-06	CI
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	24-04-17	MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	24-04-16	MT
Cybin Inc. announced that it has received $150 million in funding from a group of investors	24-03-18	CI
Sector Update: Health Care Stocks Softer Friday Afternoon	24-03-15	MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	24-03-15	MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	24-03-15	CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	24-03-14	MT

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-02-17 - Q3 2025 Earnings Release (Projected)

More about the company